Thomas Bickett

Aug 15, 2023 | cell.com | O'Byrne K.J |Jacob Gadwa |Maria Amann |Thomas Bickett

Highlights•Combined RT and PD1-IL2v drives tumor regression and increases survival•RT + PD1-IL2v initiates tumor-reactive T cell responses while limiting Treg suppression•RT + PD1-IL2v enhances NK cell activating receptor expression and cytotoxicity•Improved NK immunosurveillance controls metastatic spread to lungsSummaryThe implementation of cancer immunotherapies has seen limited clinical success in head and neck squamous cell carcinoma (HNSCC).